ANAM-17-21
10 Nov 2020
ANAM-17-21
NCT03743064
A phase III, randomised, double-blind, placebo-controlled, mutli-centre study to evaluate the efficacy and safety of anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC.
Helsinn Healthcare SA
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | NSCLC |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2018-12-18 |
Anticipated End Date | 2023-01-31 |
Hospital | Calvary Central Districts Hospital |
---|---|
Clinical Trial Coordinator | Julie Rowe |
julie.rowe@calvarycare.org.au | |
Phone | 08 8239 9536 |
Principal Investigator | Dr Vineet Kwatra |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs